Home » FDA Grants Incyte’s Jakafi Breakthrough Therapy Designation
FDA Grants Incyte’s Jakafi Breakthrough Therapy Designation
June 29, 2016
Incyte’s Jakafi has secured breakthrough therapy designation for treatment of patients with acute graft-versus-host disease, the Wilmington, Del.-based company announced last week.
Jakafi is indicated to treat people with polycythemia vera who aren’t responsive to hydroxyurea, as well as people with intermediate or high-risk myelofibrosis.
Currently, there are no approved treatments for patients with acute GVHD.
Upcoming Events
-
21Oct